This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

This study has been completed.
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01312961
First received: March 9, 2011
Last updated: June 7, 2017
Last verified: June 2017
  Purpose

Primary Objective:

To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma.

Secondary Objectives:

  • To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
  • To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.

Condition Intervention Phase
Asthma Drug: Dupilumab Drug: Placebo (for Dupilumab) Drug: Fluticasone/Salmeterol combination therapy Drug: Fluticasone monotherapy Drug: Albuterol Drug: Levalbuterol Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Percentage of Participants With Asthma Exacerbation [ Time Frame: Baseline up to Week 12 ]
    An asthma exacerbation was defined as the occurrence of any of the following: ≥30% reduction from baseline in morning PEF on 2 consecutive days; or ≥6 additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; or deterioration of asthma, as determined by the investigator, requiring systemic steroid treatment, or an increase in inhaled corticosteroid (ICS) of ≥4 times the last dose received prior to discontinuation from the study, or hospitalization. The occurrence of asthma exacerbations by individual criteria are reported.


Secondary Outcome Measures:
  • Time to First Asthma Exacerbation: Kaplan-Meier Estimates at Week 4, Week 8 and Week 12 [ Time Frame: Baseline up to Week 12 ]
    The time-to-asthma exacerbation was defined as the time from the date of randomization to the date of the first asthma exacerbation event; for participants without asthma exacerbation, it was censored at the end of treatment visit date. The median time to first asthma exacerbation was not estimated because the number of asthma exacerbations was too low in the Dupilumab arm. Therefore, alternative Kaplan-Meier statistics, the probability of asthma exacerbation at Week 4, 8 and 12, are presented as the descriptive measure statistics.

  • Percentage of Participants With Composite Asthma Events [ Time Frame: Baseline up to Week 12 ]
    Composite asthma event was defined as a 30% or greater reduction from baseline in morning PEF on 2 consecutive days together with 6 or more additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days.

  • Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12 [ Time Frame: Baseline, Week 12 ]
    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.

  • Change From Baseline in Peak Expiratory Flow (PEF) to Week 12 [ Time Frame: Baseline, Week 12 ]
    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.

  • Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12 [ Time Frame: Baseline, Week 12 ]
    ACQ-5 questionnaire is a validated questionnaire comprising of 5 questions for asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath, and wheeze. Participants were asked to rate their asthma symptoms during the previous week on a 7-point scale as 0=no impairment, 6=maximum impairment. ACQ-5 score is the mean of the 5 questions and range between 0 (disease totally controlled) and 6 (disease severely uncontrolled), a higher score indicated lower asthma control.

  • Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12 [ Time Frame: Baseline, Week 12 ]
    The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.

  • Change From Baseline in Morning Asthma Symptom Scores to Week 12 [ Time Frame: Baseline, Week 12 ]
    AM (ante meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning. No nighttime awakenings,2= Woke up once because of asthma (including early awakening),3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.

  • Change From Baseline in Evening Asthma Symptom Scores to Week 12 [ Time Frame: Baseline, Week 12 ]
    PM (post meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the day. It ranges from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.

  • Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 12 [ Time Frame: Baseline, Week 12 ]
    Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.

  • Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12 [ Time Frame: Baseline, Week 12 ]
    Number of Albuterol or Levalbuterol inhalations were recorded daily by the participants in their electronic diary as Albuterol or Levalbuterol was to be used only as needed for symptoms, not on a regular basis or prophylactically.


Enrollment: 104
Study Start Date: March 2011
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo (for Dupilumab)
Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to background therapy of inhaled corticosteroids/long-acting beta2-adrenergic agonist (ICS/LABA) (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
Drug: Placebo (for Dupilumab)
Solution for injection, one subcutaneous injection.
Drug: Fluticasone/Salmeterol combination therapy
Oral inhalation twice daily.
Drug: Fluticasone monotherapy
Oral inhalation twice daily.
Drug: Albuterol
Oral inhalation as needed.
Drug: Levalbuterol
Oral inhalation as needed.
Experimental: Dupilumab 300 mg qw
Dupilumab 300 mg SC injection qw for 12 weeks added to background therapy of ICS/LABA (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
Drug: Dupilumab
Solution for injection, one subcutaneous injection.
Other Names:
  • SAR231893
  • REGN668
Drug: Fluticasone/Salmeterol combination therapy
Oral inhalation twice daily.
Drug: Fluticasone monotherapy
Oral inhalation twice daily.
Drug: Albuterol
Oral inhalation as needed.
Drug: Levalbuterol
Oral inhalation as needed.

Detailed Description:

The total duration of the study period per participant was 20-22 weeks broken down as follows:

  • Screening period: up to 14 days,
  • Treatment period: 12 weeks,
  • Follow-up period: 6-8 weeks.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Medical diagnosis of persistent asthma for at least 12 months whose:

  • airway inflammation likely to be eosinophilic,
  • asthma partially controlled or uncontrolled on ICS plus LABA therapy.
  • On a stable dose of either Fluticasone/Salmeterol, Budesonide/Formoterol, Mometasone/Formoterol combination therapy for at least 1 month prior to screening.
  • Signed an Informed Consent Form and Health Insurance Portability and Accountability Act (HIPAA) Authorization Form.

Exclusion criteria:

  • Less than 18 years or greater than 65 years of age.
  • Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further evaluation.
  • Chronic obstructive pulmonary disease and/or other lung diseases impairing Pulmonary Function Tests.
  • Beta-adrenergic receptor blockers required for any reason.
  • Current smoker or cessation of smoking within the 6 months prior to screening.
  • Previous smoking with a smoking history >10 cigarette pack/years.
  • Participation in another study within 6 months prior to screening if the study medication was an antibody or within 30 days prior to screening for all other study medications.
  • Known or suspected non-compliance, alcohol or drug abuse.
  • Inability to follow the procedures of the study (e.g, due to language problems, psychological disorders).
  • Concomitant severe diseases or diseases for which the use of ICS or LABA were contraindicated.
  • Known allergy to doxycycline or related compounds.
  • Pregnancy or intention to become pregnant during the course of the study, breast feeding, or unwillingness to use a highly effective method of contraception throughout the study in women of childbearing potential.
  • Recent history of a parasitic infection or travel to a parasitic endemic area within 6 months prior to screening.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01312961

  Hide Study Locations
Locations
United States, California
Investigational Site Number 840047
Anaheim, California, United States, 92804
Investigational Site Number 840046
Long Beach, California, United States, 90806
Investigational Site Number 840032
Los Angeles, California, United States, 90025
Investigational Site Number 840036
Los Angeles, California, United States, 90048
Investigational Site Number 840005
Mission Viejo, California, United States, 92691
Investigational Site Number 840007
Orange, California, United States, 92868
Investigational Site Number 840048
Riverside, California, United States, 92506
Investigational Site Number 840035
Rolling Hills Estates, California, United States, 90274
Investigational Site Number 840041
San Francisco, California, United States, 94143
Investigational Site Number 840042
San Francisco, California, United States, 94143
Investigational Site Number 840039
San Jose, California, United States, 95117
Investigational Site Number 840024
Santa Rosa, California, United States, 95405
Investigational Site Number 840002
Stockton, California, United States, 95207
United States, Colorado
Investigational Site Number 840031
Colorado Springs, Colorado, United States, 80907
Investigational Site Number 840011
Denver, Colorado, United States, 80206
Investigational Site Number 840017
Denver, Colorado, United States, 80230
United States, Connecticut
Investigational Site Number 840026
New Haven, Connecticut, United States, 06510
United States, Florida
Investigational Site Number 840044
Tallahassee, Florida, United States, 32308
Investigational Site Number 840029
Tampa, Florida, United States, 33612
United States, Indiana
Investigational Site Number 840028
Indianapolis, Indiana, United States, 46208
United States, Iowa
Investigational Site Number 840038
Iowa City, Iowa, United States, 52240
United States, Kansas
Investigational Site Number 840021
Overland Park, Kansas, United States, 66210
United States, Kentucky
Investigational Site Number 840053
Owensboro, Kentucky, United States, 42303
United States, Maryland
Investigational Site Number 840014
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Investigational Site Number 840015
North Dartmouth, Massachusetts, United States, 02747
United States, Minnesota
Investigational Site Number 840003
Minneapolis, Minnesota, United States, 55402
Investigational Site Number 840010
Minneapolis, Minnesota, United States, 55402
United States, Missouri
Investigational Site Number 840006
Saint Louis, Missouri, United States, 63110
Investigational Site Number 840013
Saint Louis, Missouri, United States, 63141
United States, Montana
Investigational Site Number 840022
Bozeman, Montana, United States, 59718
United States, Nebraska
Investigational Site Number 840025
Omaha, Nebraska, United States, 68131
Investigational Site Number 840008
Papillion, Nebraska, United States, 27103
United States, New Jersey
Investigational Site Number 840018
Princeton, New Jersey, United States, 08540
United States, North Carolina
Investigational Site Number 840004
Winston-Salem, North Carolina, United States, 27157-1071
United States, Ohio
Investigational Site Number 840023
Sylvania, Ohio, United States, 43560
United States, Oklahoma
Investigational Site Number 840045
Oklahoma City, Oklahoma, United States, 73120
United States, Oregon
Investigational Site Number 840001
Lake Oswego, Oregon, United States, 97035
Investigational Site Number 840012
Medford, Oregon, United States, 97504
Investigational Site Number 840016
Portland, Oregon, United States, 97209
United States, Pennsylvania
Investigational Site Number 840040
Hershey, Pennsylvania, United States, 17033
Investigational Site Number 840037
Pittsburgh, Pennsylvania, United States, 15213
Investigational Site Number 840009
Upland, Pennsylvania, United States, 19013
United States, South Carolina
Investigational Site Number 840027
Charleston, South Carolina, United States, 29407
United States, Texas
Investigational Site Number 840030
El Paso, Texas, United States, 79902
Investigational Site Number 840050
San Antonio, Texas, United States, 78229
United States, Vermont
Investigational Site Number 840052
South Burlington, Vermont, United States, 05403
United States, Virginia
Investigational Site Number 840049
Richmond, Virginia, United States, 23229
United States, Washington
Investigational Site Number 840020
Seattle, Washington, United States, 98105
Investigational Site Number 840019
Tacoma, Washington, United States, 98415-0299
United States, Wisconsin
Investigational Site Number 840034
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Sanofi
Regeneron Pharmaceuticals
Investigators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Publications:
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT01312961     History of Changes
Other Study ID Numbers: ACT11457
U1111-1117-7826 ( Other Identifier: UTN )
Study First Received: March 9, 2011
Results First Received: April 27, 2017
Last Updated: June 7, 2017

Additional relevant MeSH terms:
Asthma
Pulmonary Eosinophilia
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Hypereosinophilic Syndrome
Eosinophilia
Leukocyte Disorders
Hematologic Diseases
Fluticasone
Salmeterol Xinafoate
Albuterol
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists

ClinicalTrials.gov processed this record on August 16, 2017